Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (789)	12/30/2002 2:48:02 PM
From: Ken W	Read Replies (1) \| Respond to of 23958

Sergio Here is the link: cms.hhs.gov There is considerable discussion as to if this is going to be a positive or not since there is some distractor included in the review dated Dec. 4th, however, in speaking with IR, Ms Ortega felt confident that the outcome would be "a good thing". While hypertension is not the end all to the sucess of the company it would be a plus to get testing for that condition covered as well. As an aside three officers filed to sell stock as did the CEO, Mr. Perry. I believe they are restricted as to sales of stock at 5.00 and over only and then only 3% of their holdings. Maybe they have an idea as to what earnings are going to be

To: Sergio H who wrote (789)	12/31/2002 12:59:41 PM
From: JoeinIowa	Respond to of 23958

This may spark some interest in ALT running into next week. Alteon to Present at JPMorgan H&Q Healthcare Conference - Presentation to be Webcast - Monday December 30, 3:03 pm ET RAMSEY, N.J., Dec. 30 /PRNewswire-FirstCall/ -- Alteon Inc. (Amex: ALT - News) announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the 21st Annual JPMorgan H&Q Healthcare Conference in San Francisco, CA, on Thursday, January 9, 2003 at 12:00 p.m. Pacific Time. ADVERTISEMENT The presentation will be available to the general public via a live webcast, accessible at www.mapdigital.com/jpmorgan/healthcare03. It will also be archived and available at the investor relations section of Alteon's website, alteon.com, later that day. Mr. Moch will outline the clinical development strategy for lead product ALT-711. Alteon's three ongoing Phase II trials of ALT-711 will be unblinded in 2003, beginning in the first quarter, with the Phase IIa DIAMOND trial in patients with diastolic heart failure. The Phase IIb SAPPHIRE/SILVER trials in systolic hypertension are expected to be unblinded about mid-year.